A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy

Yoshiya Yamada, Marisa A Kollmeier, Xin Pei, Chu Cheng Kan, Gil'ad N Cohen, Sherri M Donat, Brett W Cox, Michael J Zelefsky, Yoshiya Yamada, Marisa A Kollmeier, Xin Pei, Chu Cheng Kan, Gil'ad N Cohen, Sherri M Donat, Brett W Cox, Michael J Zelefsky

Abstract

Purpose: We report the toxicity and biochemical tumor control outcome of a prospective Phase II study using high-dose-rate brachytherapy (HDR) alone as a salvage therapy for recurrent disease after external beam radiotherapy (EBRT).

Methods: Forty-two patients with biopsy-proven recurrence were enrolled on a Phase II study of salvage HDR monotherapy using iridium-192. Median pretreatment EBRT dose was 8100 cGy (6840-8640 cGy) and the median time from completion of EBRT to salvage HDR was 73 months. The protocol prescription dose of 3200 cGy was delivered in four fractions over 30 hours in a single insertion. Median followup after salvage HDR was 36 months (6-67 months).

Results: The actuarial prostate-specific antigen biochemical relapse-free survival and distant metastases-free survival rates at 5 years were 68.5% and 81.5%, respectively. Cause-specific survival was 90.3%. Late genitourinary Grade 1and 2 toxicities were found in 38% and 48%, respectively, and one patient developed Grade 3 urinary incontinence. Late Grade 1 and 2 gastrointestinal toxicity was noted in 17% and 8% of patients, respectively. Three patients (7%) developed Grade 2 late urinary toxicity (urethral stricture), which were corrected with urethral dilatation, and one patient developed Grade 3 urinary incontinence. No Grade 4 toxicities were observed.

Conclusions: Genitourinary toxicity was the most commonly encountered toxicity observed after salvage HDR but severe toxicities were uncommon. Salvage HDR is an effective and well-tolerated modality for locally recurrent prostate cancer and should be considered even for patients who have previously been treated with ultra-high dose levels of EBRT.

Keywords: High dose rate brachytherapy; Salvage brachytherapy.

Copyright © 2014 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
PSA relapse-free survival. PSA = prostate-specific antigen; HDR = high-dose-rate brachytherapy.
Fig. 2
Fig. 2
Distant metastases-free survival. HDR = high-dose-rate brachytherapy.
Fig. 3
Fig. 3
Grade 2 GI and Grade 2 GU toxicity–free toxicity survival curve. GI =gastrointestinal; GU = genitourinary; HDR = high-dose-rate brachytherapy.

References

    1. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033.
    1. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–1620.
    1. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337.
    1. Spratt DE, Pei X, Yamada J, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:686–692.
    1. Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011;60:1133–1139.
    1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74.
    1. Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-Year outcomes. Int J Radiat Oncol Biol Phys. 2013;86:324–329.
    1. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157–164.
    1. Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 2008;179:1368–1373. discussion 1373.
    1. Kuban DA, el-Mahdi AM, Schellhammer PF. Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer. 1989;63:2421–2425.
    1. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: A comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–1513.
    1. Bianco FJ, Jr, Scardino PT, Stephenson AJ, et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:448–453.
    1. Paparel P, Cronin AM, Savage C, et al. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol. 2009;55:404–410.
    1. Perrotte P, Litwin MS, McGuire EJ, et al. Quality of life after salvage cryotherapy: The impact of treatment parameters. J Urol. 1999;162:398–402.
    1. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: A seven-year follow-up. Clin Prostate Cancer. 2003;2:111–114.
    1. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: Identifying predictors of treatment failure and complications. J Urol. 2001;165:1937–1941. discussion 1941–1942.
    1. Grado GL. Benefits of brachytherapy as salvage treatment for radiorecurrent localized prostate cancer. Urology. 1999;54:204–207.
    1. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54:880–883.
    1. Aaronson DS, Yamasaki I, Gottschalk A, et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009;104:600–604.
    1. Burri RJ, Stone NN, Unger P, et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77:1338–1344.
    1. Spratt DE, Scala LM, Folkert M, et al. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy. 2013;12:428–433.
    1. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106–1112.
    1. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: Morbidity revisited. J Urol. 2000;164:1998–2001.
    1. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: Variables affecting patient outcome. J Clin Oncol. 2002;20:2664–2671.
    1. Ismail M, Ahmed S, Kastner C, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: A prospective case series of the first 100 patients. BJU Int. 2007;100:760–764.
    1. Bahn D, de Castro Abreu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012;62:55–63.
    1. Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol. 2006;176:2020–2024.
    1. Allen GW, Howard AR, Jarrard DF, et al. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007;110:1405–1416.
    1. Nguyen PL, D’Amico AV, Lee AK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature. Cancer. 2007;110:1417–1428.
    1. Lee HK, Adams MT, Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy. 2008;7:17–21.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe